Pregnancy outcomes of women receiving compounded 17 α- hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011

American Journal of Perinatology

Volumn 29, Issue 8, 2012, Pages 635-642

  Sibai, Baha M ^a   Istwan, Niki B ^b   Palmer, Beverly ^b   Stanziano, Gary J ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Women's and Children's Health ^*  (United States)

Author keywords

17 alpha hydroxyprogesterone caproate; compounded 17P; Makena; preterm birth prevention; safety

Indexed keywords

HYDROXYPROGESTERONE CAPROATE;

ADULT; ARTICLE; BIRTH RATE; FEMALE; FETUS MORTALITY; GESTATIONAL AGE; HOME CARE; HUMAN; INJECTION SITE ABSCESS; INJECTION SITE CONTUSION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; NEGRO; NEWBORN MORTALITY; PATIENT COMPLIANCE; PATIENT SAFETY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; DRUG PACKAGING; FEMALE; FETAL DEATH; HOME CARE SERVICES; HUMANS; HYDROXYPROGESTERONES; INFANT MORTALITY; INFANT, NEWBORN; PREGNANCY; PREGNANCY OUTCOME; PREMATURE BIRTH; PROGESTINS;

EID: 84865103175     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0032-1311979     Document Type: Article

References (24)

1. Meis PJ, Klebanoff M, Thom E., et al. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med: 2003; 348 2379 2385
2. American College of Obstetricians and Gynecologists ACOG Committee Opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol: 2003; 102 5 Pt 1 1115 1116
3. Society for Maternal Fetal Medicine Publications Committee ACOG Committee Opinion number 419 October 2008 (replaces No. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol: 2008; 112 963 965
4. Ness A, Dias T, Damus K, Burd I, Berghella V. Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey. Am J Obstet Gynecol: 2006; 195 1174 1179
5. US Food and Drug Administration. Safety: heparin sodium injection. June 2010. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ ucm219000.htm. Accessed February 28, 2011
6. Gershanik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med: 1982; 307 1384 1388
7. CDC MMWR Weekly. Neonatal deaths associated with use of benzyl alcoholUnited States. June 11, 1982;31:290-291. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm. Accessed December 12, 2011
8. Food and Drug Administration, Center for Drug Evaluation and Research. Statistical review and evaluation, Clinical studies; NDA 21-945. Reference ID: 2900768. Available at: www.fda.gov/downloads/drugs/developmentapprovalprocess/ developmentresources/ucm252978.pdf. Accessed January 9, 2012
9. Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting. Am J Obstet Gynecol: 2007; 197 262, e1-e4
10. Rebarber A, Fox NS, Klauser CK., et al. Using 17 α- hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice. J Matern Fetal Neonatal Med: 2010; 23 1139 1142
11. González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med: 2007; 20 249 252
12. How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter? Am J Obstet Gynecol: 2007; 197 260, e1-e4
13. Rebarber A, Ferrara LA, Hanley ML., et al. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol: 2007; 196 224, e1-e4
14. Rebarber A, Cleary-Goldman J, Istwan NB., et al. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage. Am J Perinatol: 2008; 25 271 275
15. Ventolini G, Duke J, Po W., et al. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate. J Reprod Med: 2008; 53 667 671
16. Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention. Am J Perinatol: 2010; 27 343 348
17. Gonzalez-Quintero VH, Cordova YC, Istwan NB., et al. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery. Am J Obstet Gynecol: 2011; 205 275, e1-e5
18. González-Quintero VH, de la Torre L, Rhea DJ., et al. Impact of prior gestational age at preterm delivery on effectiveness of 17-alpha-hydroxyprogesterone caproate in practice. Am J Obstet Gynecol: 2010; 203 257, e1-e5
19. Barton JR, Barton LA, Istwan NB, Rhea DJ, Desch CN, Sibai BM. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence? Am J Obstet Gynecol: 2011; 205 269, e1-e6
20. Coleman S, Wallace L, Alexander J, Istwan N. Recurrent preterm birth in women treated with 17 alpha-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy. J Matern Fetal Neonatal Med: 2011;; October 12 (Epub ahead of print)
21. Rebarber A, Istwan NB, Russo-Stieglitz K., et al. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Diabetes Care: 2007; 30 2277 2280
22. O'Brien JM, Ho SJ, Istwan NB, Stanziano GJ, Rhea DJ, Barton JR. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study. Am J Perinatol: 2010; 27 157 162
23. KV Pharmaceuticals. Independent laboratory testing demonstrates important quality differences between FDA approved Makena® and compounded 17P formulations. Press release November 8, 2011. Available at: www.kvph.com/news- center-article.aspx. Accessed January 9, 2012
24. US Food and Drug Administration. FDA statement on Makena, November 8, 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm279098.htm. Accessed December 12, 2011.